Rwanda medical device regulations

Rwanda FDA's reliance guideline: the principles it applies when it recognises another regulator's work, the reliance pathways it offers, the areas where it will rely (marketing authorization, GMP inspections, vigilance, clinical trials, quality-control testing, market surveillance and control) and the procedure and documentation for a reliance application. Revision 3, effective 23/02/2024 on the document's own statement, first issued 14/06/2021. It is a medicines-and-devices instrument rather than a device-only one, and it is the reliance text a device applicant reaches for in this market.

The technical regulations that carry Rwanda's device registration obligation: 40 articles across four chapters, from classification and the application dossier through assessment, the certificate, validity, variations, renewal, suspension and cancellation to labelling and the restriction on selling unregistered devices. Two articles matter beyond registration and are why this is the market's lead instrument: Article 16 ("Reliance") and Article 31 (label and labelling of medical devices or IVDs). The copy states "Date for coming into effect 20th April 2020" and its revision history records revision 0 on 20/04/2020 (first issue), revision 1 on 08/06/2021 and revision 2 on 22/08/2022, so the row's effective date is the date the document states and the revisions are recorded here. Chapter headings in the extract follow the document's own casing, including its "Chapter Ii" — the source's typography, not repaired.

The registration guideline the technical regulations are worked through: the application route, the classification statement, the QMS expectation, the review committee and the timelines, followed by the dossier itself laid out as the submission's own chapters — administrative information (1.01–1.15), submission context (2.01–2.11), non-clinical evidence (3.01–3.11), clinical evidence (4.01–4.07), labelling (5.01–5.10), the quality management system evidence (6.01–6.17) — and five appendices. It is dated NOVEMBER, 2025 on its cover, and its own "Effective date of this revision" field is left blank in the published copy (literally "...."), so no effective date is recorded: the blank is the source's and is not filled with the cover month. The publisher's file name says December 2025 against the cover's November; the cover is what the row follows. Version 2 is the current revision of a guideline the Authority first issued under the same document number.

The Authority's fees regulations: eleven articles (purpose, citation, application, definitions, the service tariff, duration for payment, appeal, exemption, revision, commencement and repealing provisions) and three annexes, of which Annex I is the fee schedule itself — registration and marketing authorization of imported products, domestic manufacturing licences, variations, renewals, clinical-trial approval, wholesale/distributor/importer licences, GMP inspections, importation fees and the services shared with the Rwanda Standards Board. Every device fee an applicant pays against comes from this schedule. Version 5, signed 31 December 2024, first issued 15/11/2019. The document is trilingual: Annex I is printed in Kinyarwanda, then English, then French, with Annexes II and III after each printing. One document, so one expression — the extract carries all three printings and its catalog label says so; the extract's `language` is recorded as `en`, the working language the market reads and the language the fee lines are cited in.